Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Neumora Therapeutics in a report released on Wednesday, November 13th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($1.63) per share for the year, down from their previous forecast of ($1.37). HC Wainwright currently has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Neumora Therapeutics' Q4 2024 earnings at ($0.46) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($1.37) EPS and FY2028 earnings at $0.03 EPS.
A number of other brokerages also recently commented on NMRA. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and reduced their target price for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. Needham & Company LLC restated a "buy" rating and set a $23.00 price objective on shares of Neumora Therapeutics in a report on Wednesday. Finally, Royal Bank of Canada restated an "outperform" rating and set a $29.00 price objective on shares of Neumora Therapeutics in a report on Wednesday, September 4th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $21.67.
Check Out Our Latest Stock Analysis on NMRA
Neumora Therapeutics Price Performance
Neumora Therapeutics stock traded down $0.85 during trading hours on Friday, reaching $10.84. The stock had a trading volume of 956,435 shares, compared to its average volume of 730,514. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -5.84 and a beta of 3.92. The business's 50 day moving average price is $13.09 and its 200-day moving average price is $11.41. Neumora Therapeutics has a 52 week low of $8.33 and a 52 week high of $21.00.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.07). During the same period last year, the company posted ($1.14) EPS.
Institutional Investors Weigh In On Neumora Therapeutics
A number of large investors have recently bought and sold shares of the company. Amalgamated Bank boosted its position in Neumora Therapeutics by 472.8% in the 2nd quarter. Amalgamated Bank now owns 2,910 shares of the company's stock worth $29,000 after purchasing an additional 2,402 shares in the last quarter. Handelsbanken Fonder AB boosted its position in Neumora Therapeutics by 35.0% in the 3rd quarter. Handelsbanken Fonder AB now owns 26,600 shares of the company's stock worth $351,000 after purchasing an additional 6,900 shares in the last quarter. Quarry LP purchased a new stake in Neumora Therapeutics in the 2nd quarter worth approximately $98,000. Intech Investment Management LLC purchased a new stake in Neumora Therapeutics in the 3rd quarter worth approximately $175,000. Finally, Ballentine Partners LLC purchased a new stake in Neumora Therapeutics in the 3rd quarter worth approximately $178,000. Hedge funds and other institutional investors own 47.65% of the company's stock.
Insider Activity at Neumora Therapeutics
In related news, CFO Joshua Pinto sold 28,496 shares of the company's stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $11.63, for a total value of $331,408.48. Following the sale, the chief financial officer now owns 210,469 shares in the company, valued at $2,447,754.47. This represents a 11.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Matthew K. Fust sold 14,049 shares of the company's stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the sale, the director now owns 20,100 shares in the company, valued at approximately $342,303. This represents a 41.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 110,538 shares of company stock worth $1,390,513 over the last quarter. Insiders own 26.40% of the company's stock.
About Neumora Therapeutics
(
Get Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Featured Stories
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
